ADMA Biologics vs Repligen
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put ADMA Biologics and Repligen side by side, using each one’s latest annual report. Here is what stands out:
- Repligen is the larger business, with $738M of revenue in fiscal 2025 against $510M for ADMA Biologics.
- ADMA Biologics grew revenue faster (19.6%, against 16.4%).
- ADMA Biologics kept more of each dollar of sales as operating profit (37.5% operating margin, against 7.5%).
- Repligen turned more of its sales into free cash flow (12.7% FCF margin, against 5.5%).
- ADMA Biologics earned a higher return on the capital invested in it (39.5%, against 2.4%).
Who comes out ahead
Of the 9 measures where higher (or lower) is clearly better, how many each company leads.
ADMA Biologics
ADMA
7/9
Revenue growth5-year growthGross marginOperating marginNet marginReturn on capitalReturn on equity
Repligen
RGEN
2/9
FCF marginNet debt / EBITDA
Side by side
Best in the row
| Latest fiscal year | ADMA FY25 | RGEN FY25 |
|---|---|---|
| Size | ||
| Market cap | $2.5B | — |
| Revenue | $510M | $738M |
| Free cash flow | $27.8M | $93.9M |
| Net income | $147M | $48.9M |
| Growth | ||
| Revenue growth | 19.6% | 16.4% |
| 5-year growth | 64.6% | 15.1% |
| Share count change | 0.6% | — |
| Profitability | ||
| Gross margin | 57.4% | 52.3% |
| Operating margin | 37.5% | 7.5% |
| Net margin | 28.8% | 6.6% |
| FCF margin | 5.5% | 12.7% |
| Return on capital | 39.5% | 2.4% |
| Return on equity | 35.6% | 2.4% |
| Balance sheet | ||
| Net debt | −$15.5M | −$225M |
| Net debt / EBITDA | −0.1x | −1.7x |
| Dividends and buybacks | $31.9M | $0.0M |
| Valuation & quality | ||
| P/E | 15.3x | — |
| Piotroski F-score | 5 | — |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.